Clinical trials recruiting in Hubei, China

Phase breakdown

Conditions recruiting in Hubei, China

Recruiting trials in Hubei, China

• A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
  NCT05276726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
  NCT06609005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male
• A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
  NCT07262333 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Chinese Psoriasis Real World Evidence Research
  NCT04465838 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
  NCT06809764 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
  NCT06953089 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Preliminary Human Trials of F230 Tablets
  NCT06899815 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female)
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
  NCT06542588 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
  NCT06909773 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female)
• This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis
  NCT07303790 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Hubei, China?

12 recruiting trials have at least one study site in Hubei, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.